You are here

P&T News

May 31

Most regret the decision to change systems, survey finds
30-day readmission rate drops from 19% to 13%
Treatment may cause severe liver injury
Farnesoid X receptor agonist reduces alkaline phosphatase

May 27

Finding may herald emergence of pan–drug-resistant bugs
Probuphine provides low-level buprenorphine for six months
First recombinant factor VIII single-chain therapy
Manufacturing issues sink ZS-9 application

May 26

If approved, drug would be first single-dose oral therapy for BV
Class-action complaint alleges misrepresentation, false advertising
Publication outlines implementation strategies in acute care
Approval decision expected in July

May 25

Implanted rods offer controlled release of buprenorphine
Monoclonal antibody targets nerve growth factor
Advisors voted 7–3 against approval, but patient advocates clamor for a cure
Xaracoll is on schedule for 2017 launch

Pages